The percentage on each card is TRVI's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● Seeking AlphaNov 9, 2026 · 19:50 ET
Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript…
What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call
Trevi Therapeutics NASDAQ: TRVI said it remains on track to report results from its lead chronic cough trials in 2027 and 2028, while preparing a new study in patients with interstitial lung disease other than idiopathic…
● GlobeNewsWireNov 9, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough progr…
● GlobeNewsWireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatme…
● GlobeNewsWireOct 27, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET…
● GlobeNewsWireOct 13, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Professor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) Professor Ph…
● GlobeNewsWireSep 3, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Trevi Therapeutics to Participate in Upcoming September Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatm…
● GlobeNewsWireAug 26, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough…
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing…
Article counts from the last market-wide feed page, across every symbol we track and not just TRVI · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.